Generation of Stable CD4+and CD8+T Cell Lines from Patients Immunized withrasOncogene-Derived Peptides Reflecting Codon 12 Mutations

This publication has 29 references indexed in Scilit:

• Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
  The Lancet, 1995
• Peptide‐specific activation of cytolytic CD4⁺ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21
  European Journal of Immunology, 1995
• Induction and characterization of cytotoxic T‐lymphocytes recognizing a mutated p21ras peptide presented by HLA‐A*0201
  International Journal of Cancer, 1995
• Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
  The Journal of Experimental Medicine, 1994
• Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cells
  European Journal of Immunology, 1993
• Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
  Cell, 1993
• T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides
  Human Immunology, 1992
• Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
  Nature, 1991
• Identical peptides recognized by MHC class I- and II-restricted T cells.
  The Journal of Experimental Medicine, 1989
• Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations
  Nature, 1983